These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27148906)

  • 1. Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review.
    Pang A; Carbini M; Maki RG
    JAMA Oncol; 2016 Jul; 2(7):941-7. PubMed ID: 27148906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
    Ratan R; Patel SR
    Curr Treat Options Oncol; 2017 Jun; 18(6):34. PubMed ID: 28534249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
    Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
    Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In brief: Two Drugs for soft-tissue sarcoma.
    Med Lett Drugs Ther; 2016 May; 58(1494):e62. PubMed ID: 27148925
    [No Abstract]   [Full Text] [Related]  

  • 5. Heterogeneous and Rare: Toward Histology-Specific Treatment of Soft-Tissue Sarcoma.
    Azvolinsky A
    J Natl Cancer Inst; 2016 Jun; 108(6):djw161. PubMed ID: 27257028
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
    Sharma S; Takyar S; Manson SC; Powell S; Penel N
    BMC Cancer; 2013 Aug; 13():385. PubMed ID: 23937858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabectedin in soft tissue sarcomas.
    Petek BJ; Loggers ET; Pollack SM; Jones RL
    Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
    Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trabectedin in advanced soft tissue sarcoma: case series.
    Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
    J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
    Le Cesne A; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
    Le Cesne A
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease.
    Schöffski P; Cornillie J; Wozniak A; Li H; Hompes D
    Oncol Res Treat; 2014; 37(6):355-62. PubMed ID: 24903768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.
    Le Cesne A; Domont J; Cioffi A; Bonvalot S; Terrier P; Ray-Coquard I; Alfaro V; Lebedinsky C; Santabarbara P; Blay JY
    Drugs Today (Barc); 2009 Jun; 45(6):403-21. PubMed ID: 19649331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of chemotherapy for patients with bone and soft-tissue sarcomas.
    Wesolowski R; Budd GT
    Cleve Clin J Med; 2010 Mar; 77 Suppl 1():S23-6. PubMed ID: 20179184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.
    Prescrire Int; 2009 Aug; 18(102):161. PubMed ID: 19743575
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
    Martin-Liberal J; Judson I
    Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
    Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
    Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
    Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
    Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
    Simpson EL; Rafia R; Stevenson MD; Papaioannou D
    Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.